How should functionally equivalent drugs be reimbursed?: A retrospective analysis of reimbursement for epoetin alfa and Darbepoetin alfa in 2001–3 and the cost implications for CMS
Kanavos, P.
& Saka, O.
(2005).
How should functionally equivalent drugs be reimbursed?: A retrospective analysis of reimbursement for epoetin alfa and Darbepoetin alfa in 2001–3 and the cost implications for CMS.
Disease Management and Health Outcomes,
13(6), 359-370.
& Saka, O.
(2005).
How should functionally equivalent drugs be reimbursed?: A retrospective analysis of reimbursement for epoetin alfa and Darbepoetin alfa in 2001–3 and the cost implications for CMS.
Disease Management and Health Outcomes,
13(6), 359-370.